GANX
$2.62
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Recent News
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gain Therapeutics’ (GANX) Preclinical Momentum Drives Its Progress in Parkinson’s Drug Development
Gain Therapeutics’s (NASDAQ:GANX) is one of the 12 hot penny stocks to invest in right now. At the Society for Neuroscience annual meeting in San Diego on November 20, Gain Therapeutics, Inc. (NASDAQ:GANX) unveiled new preclinical data on its lead drug candidate, GT-02287. GT-02287, a small molecule, focuses on treating Parkinson’s disease (PD) by restoring […]
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Gain Therapeutics, Inc. (NASDAQ:GANX) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President Donald […]